PLI Schemes Attract Over ₹2.40 Lakh Crore Investment, Generate More Than 14.15 Lakh Jobs

I have sufficient facts (>4 from Tier-1 PIB sources) covering investment, employment, exports, sector breakdown, and background. Writing the study note.

1. At a Glance

2. Why in the News

3. Background & Evolution

4. Core Static Facts

Parameter Detail
Scheme type Production Linked Incentive (PLI)
Launch year 2020
Sectors covered 14
Nodal department DPIIT, Ministry of Commerce & Industry [S1]
Approved outlay ₹1.91 lakh crore [S1]
Cumulative investment (as on 31.03.2026) >₹2.40 lakh crore [S1]
Employment generated >14.15 lakh (direct + indirect) [S1]
Cumulative exports ₹15.2 lakh crore [S1]
Applications approved (as on Dec 2025) 836 [S3]

14 Sectors: Mobile Manufacturing & Specified Electronic Components; Critical KSMs/Drug Intermediates & APIs; Medical Devices; Automobiles & Auto Components; Pharmaceuticals Drugs; Specialty Steel; Telecom & Networking Products; Electronic/Technology Products; White Goods (ACs & LEDs); Food Products; Textile Products (MMF segment & technical textiles); High Efficiency Solar PV Modules; Advanced Chemistry Cell (ACC) Battery; Drones & Drone Components. [S3]

5. Multi-Dimensional Analysis

Economic - Investment leverage: ₹1.91 lakh crore outlay has catalysed over ₹2.40 lakh crore actual investment — a positive multiplier signal for a subsidy scheme. [S1] - Export growth trajectory sharply upward: FY24 ₹4.0 lakh crore → FY25 ₹6.5 lakh crore → FY26 ₹15.2 lakh crore (cumulative), showing acceleration in sectors like electronics and pharma. [S1]

Employment - Over 14.15 lakh direct and indirect jobs, with Food Products (3.29 lakh) and Large Scale Electronics (1.69 lakh) as top employment generators among reported sectors. [S1]

Administrative - Multi-ministry implementation structure (DPIIT nodal + line ministries) creates coordination and monitoring challenges across 14 disbursing authorities. [S1]

Scientific/Technological - Import substitution effect: mobile phone production up 2.4x, mobile imports down ~77%; domestic manufacture of 1,931 pharma products; 55,000 MT bulk drug capacity across 26 APIs; 55 unique medical devices commissioned — indicating deepening of value chains, not just assembly. [S1]

Strategic (China+1 / self-reliance) - Sectors chosen (electronics, ACC batteries, solar PV, specialty steel, APIs) map directly onto import-dependence and strategic-autonomy concerns (Atmanirbhar Bharat), particularly reducing pharma API and electronics import dependence on China. [S1][S3]

6. Recent Developments (last 12-18 months)

7. Prelims Hooks

8. Mains Relevance

9. Related Topics to Study Next

10. Common Errors / Trap Areas

11. Sources